Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2009, Article ID 275072, 5 pages
http://dx.doi.org/10.1155/2009/275072
Clinical Study

Correlation of Plasma MMP-1 and TIMP-1 Levels and the Colonic Mucosa Expressions in Patients with Ulcerative Colitis

1Department of Gastroenterology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, China
2Department of Gastroenterology, Affiliated Xinhua Hospital of Dalian University, Dalian, Liaoning 116023, China

Received 14 May 2009; Revised 18 August 2009; Accepted 25 August 2009

Academic Editor: Oreste Gualillo

Copyright © 2009 Ying-De Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. von Lampe, B. Barthel, S. E. Coupland, E.-O. Riecken, and S. Rosewicz, “Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease,” Gut, vol. 47, no. 1, pp. 63–73, 2000. View at Publisher · View at Google Scholar
  2. Y.-D. Wang and P.-Y. Yan, “Expression of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in ulcerative colitis,” World Journal of Gastroenterology, vol. 12, no. 37, pp. 6050–6053, 2006. View at Google Scholar · View at Scopus
  3. C. Medina, S. Videla, A. Radomski et al., “Increased activity and expression of matrix metalloproteinase-9 in a rat model of distal colitis,” American Journal of Physiology, vol. 284, no. 1, pp. 116–122, 2003. View at Google Scholar · View at Scopus
  4. B. C. McKaig, D. McWilliams, S. A. Watson, and Y. R. Mahida, “Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease,” American Journal of Pathology, vol. 162, no. 4, pp. 1355–1360, 2003. View at Google Scholar · View at Scopus
  5. L. M. Matrisian, “The matrix-degrading metalloproteinases,” BioEssays, vol. 14, no. 7, pp. 455–463, 1992. View at Google Scholar · View at Scopus
  6. P. Di Sebastiano, F. F. di Mola, L. Artese et al., “Beneficial effects of Batimastat (BB-94), a matrix metalloproteinase inhibitor, in rat experimental colitis,” Digestion, vol. 63, no. 4, pp. 234–239, 2001. View at Publisher · View at Google Scholar
  7. A. Stallmach, C. C. Chan, K.-W. Ecker et al., “Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis,” Gut, vol. 47, no. 3, pp. 415–422, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Wiercinska-Drapalo, J. Jaroszewicz, R. Flisiak, and D. Prokopowicz, “Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 as biomarkers of ulcerative colitis activity,” World Journal of Gastroenterology, vol. 9, no. 12, pp. 2843–2845, 2003. View at Google Scholar · View at Scopus
  9. M. N. Holten-Andersen, I. J. Christensen, H. J. Nielsen et al., “Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer,” Clinical Cancer Research, vol. 8, no. 1, pp. 156–164, 2002. View at Google Scholar · View at Scopus
  10. B. C. McKaig, D. McWilliams, S. A. Watson, and Y. R. Mahida, “Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease,” American Journal of Pathology, vol. 162, no. 4, pp. 1355–1360, 2003. View at Google Scholar · View at Scopus
  11. H. Kai, H. Ikeda, H. Yasukawa et al., “Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes,” Journal of the American College of Cardiology, vol. 32, no. 2, pp. 368–372, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Pellegrini, I. Contasta, A. M. Berghella, E. Gargano, C. Mammarella, and D. Adorno, “Simultaneous measurement of soluble carcinoembryonic antigen and the tissue inhibitor of metalloproteinase TIMP1 serum levels for use as markers of pre-invasive to invasive colorectal cancer,” Cancer Immunology Immunotherapy, vol. 49, no. 7, pp. 388–394, 2000. View at Google Scholar · View at Scopus
  13. K. M. Walsh, P. Timms, S. Campbell, R. N. M. MacSween, and A. J. Morris, “Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and-2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C. Comparison using ROC analysis,” Digestive Diseases and Sciences, vol. 44, no. 3, pp. 624–630, 1999. View at Google Scholar · View at Scopus
  14. H. Ruokolainen, P. Pääkkö, and T. Turpeenniemi-Hujanen, “Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and week squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein,” Clinical Cancer Research, vol. 11, no. 9, pp. 3257–3264, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. F. M. Brennan, K. A. Browne, P. A. Green, J.-M. Jaspar, R. N. Maini, and M. Feldmann, “Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-α (cA2) therapy,” British Journal of Rheumatology, vol. 36, no. 6, pp. 643–650, 1997. View at Google Scholar · View at Scopus
  16. M. N. Holten-Andersen, I. J. Christensen, H. J. Nielsen et al., “Measurement of the noncomplexed free fraction of tissue inhibitor of metalloproteinases I in plasma by immunoassay,” Clinical Chemistry, vol. 48, no. 8, pp. 1305–1313, 2002. View at Google Scholar · View at Scopus